Nexus Pharmaceuticals
Yi-Yu Lin is a highly experienced formulation scientist with a comprehensive background in the biopharmaceutical industry. Currently serving as the Lead Formulation Scientist at Nexus Pharmaceuticals, Inc. since December 2020, Yi-Yu Lin previously held the position of Senior Formulation Scientist. Prior experience includes roles as Scientist II at Arcturus Therapeutics and Research Scientist at TLC Biopharmaceuticals, Inc., where contributions spanned from June 2013 to December 2020. Yi-Yu Lin began professional career as an Associate Researcher at Taiwan Liposome Company, Ltd. from August 2011 to June 2013. Academic credentials include a Doctor of Philosophy (Ph.D.) degree in Biomedical Imaging and Radiological Sciences from National Yang Ming University, obtained in 2011.
Nexus Pharmaceuticals
Nexus Pharmaceuticals is a US-based, family-owned, minority-owned healthcare company and proud diverse supplier. We specialize in innovative processes to make difficult-to-manufacture specialty drugs that are easier to use, less labor-intensive, and more streamlined in practice. Nexus ensures that its high-quality, FDA-approved drugs fulfill a critical, unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. We are in the process of building Project Tomorrow – a state-of-the-art manufacturing facility in Pleasant Prairie, Wisconsin and only project of its kind in the last 30 years. Read about our commitment to Wisconsin and see our progress at nexuspharma.net/project-tomorrow